A comparison of three sources of information to guide the Bayesian design of a trial in the rare cancer Merkel-cell carcinoma


Year:

Session type:

Mark Pritchard1, Lucinda Billingham1, Jeremy Marsden2, Neil Steven1

1Cancer Research UK Clinical Trials Unit, University of Birmingham, UK, 2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Abstract

Background

Merkel-cell carcinoma (MCC) is a rare cancer of the skin.